Sugi Predict

Sugi Predict / Compounds / SCHEMBL157171

SCHEMBL157171

SCHEMBL157171

CCN1CCCC1c1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.66
▸ CHRNA7 P36544 4/20 0.66
▸ CHRNB2 P17787 4/20 0.66
▸ CHRNA4 P43681 4/20 0.66
▸ CHRNB4 P30926 2/20 0.66
▸ CHRNA3 P32297 2/20 0.66
▸ CHRNA2 Q15822 2/20 0.66
▸ TDP1 Q9NUW8 2/20 0.66
▸ LMNA P02545 1/20 0.66
▸ HTR3E A5X5Y0 1/20 0.66
▸ PSIP1 O75475 1/20 0.66
▸ TRPA1 O75762 1/20 0.66
▸ HTR3B O95264 1/20 0.66
▸ CHRNA1 P02708 1/20 0.66
▸ CHRNG P07510 1/20 0.66
▸ MAPT P10636 1/20 0.66
▸ CHRNB1 P11230 1/20 0.66
▸ CYP2A6 P11509 1/20 0.66
▸ PTGS1 P23219 1/20 0.66
▸ CHRNA5 P30532 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28497766 1.00 ALDH1A1 (0.66) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL29683697 1.00 ALDH1A1 (0.66) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL29606745 1.00 ALDH1A1 (0.66) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL18862020 0.95 CHRNB2 (0.67) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL3369061 0.85 ALDH1A1 (0.61) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL854070 0.85 ALDH1A1 (0.61) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL20590950 0.85 ALDH1A1 (0.62) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL2683364 0.85 ALDH1A1 (0.61) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL5963595 0.85 ALDH1A1 (0.62) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4
SCHEMBL26763857 0.84 ALDH1A1 (0.61) ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118830649-A Methyl nicotine salt and preparation method thereof, atomized liquid, atomizer and electronic atomization device 东莞市吉纯生物技术有限公司 2024-10-25 — — CN claimed
CN-119264106-B Preparation method and purification method of chiral 6-methyl nicotine 深圳格林凯特医药技术有限公司 2025-06-24 — — CN disclosed
CN-119264106-A Preparation method and purification method of chiral 6-methyl nicotine 深圳格林凯特医药技术有限公司 2025-01-07 — — CN disclosed
CN-118830649-A Methyl nicotine salt and preparation method thereof, atomized liquid, atomizer and electronic atomization device 东莞市吉纯生物技术有限公司 2024-10-25 — — CN disclosed
CN-118830649-A Methyl nicotine salt and preparation method thereof, atomized liquid, atomizer and electronic atomization device 东莞市吉纯生物技术有限公司 2024-10-25 — — CN disclosed
CN-118436116-A Nicotine and its derivative and preparation method 深圳市吉迩科技有限公司 2024-08-06 — — CN disclosed
CN-117925746-A Enzymatic conversion preparation method of 2-methyl-5- [ (2S) -1-methylpyrrolidine-2-yl ] pyridine 仙居两山生物科技有限公司 2024-04-26 — — CN disclosed
CN-115611858-B Method for preparing nicotine and its derivatives 深圳市真味生物科技有限公司 2024-03-29 — — CN disclosed
WO-2024000877-A1 PREPARATION METHOD FOR NICOTINE 湖北和诺生物工程股份有限公司 2024-01-04 — — WO disclosed
CN-114437031-B Synthesis method of 6-methyl nicotine 深圳市真味生物科技有限公司 2023-06-27 — — CN disclosed
CN-102245200-A Nicotine immunonanotherapeutics MASSACHUSETTS INST TECHNOLOGY 2011-11-16 — — CN disclosed
US-7531539-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-05-12 — — US disclosed
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 — — US disclosed
US-20080045496-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US disclosed
CN-100341482-C Substituted hydrocarbyl functional siloxanes for household, health, and personal care applications DOW CORNING (US) 2007-10-10 — — CN disclosed
CN-1655755-A Substituted hydrocarbyl functional siloxanes for use in daily, health and personal care applications DOW CORNING (US) 2005-08-17 — — CN disclosed
US-20020051821-A1 Aliginate particle formulation KWON SUNG-YUN (US) 2002-05-02 — — US disclosed
WO-2002019989-A2 ALGINATE PARTICLE FORMULATION POWDERJECT RESEARCH LIMITED (GB) 2002-03-14 — — WO disclosed
US-5804202-A MIXING TOPICAL ADJUVANT WITH WATER IN OIL EMULSION CONTAINING ACRYLAMIDE, 2-ACRYLAMIDO-2-METHYLPROPANESULFONIC ACID, AND ALLYL SUCROSE, ALLYL PENTAERYTHRITOL, OR METHYLENE-BISACRYLAMIDE; SKIN, HAIR CARE PRODUCTS SCOTT BADER COMPANY LIMITED (GB) 1998-09-08 — — US disclosed
WO-1994004152-A1 NICOTINE DERIVATIVES THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1994-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC6 ALDH1A1 828/4885CHRNA7 4485/4885CHRNB2 4595/4885
US-20080045496-A1 PYRROLOTRIAZINE KINASE INHIBITORS JAK2, NTRK2, NTRK3 ALDH1A1 3191/4885CHRNA7 1622/4885CHRNB2 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.